Patrik Brundin
Titel
Professor
Organisation
046-2220529
Patrik [dot] Brundin [at] med [dot] lu [dot] se
Publikationer (hämtat ur Lunds universitets publikationsdatabas)
författare
- 2013
- Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion-Like Disorder?
- Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.
- What's to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease?
- α-Synuclein: The Long Distance Runner.
- 2012
- Can Parkinson's disease pathology be propagated from one neuron to another?
- Late onset vascular dysfunction in the R6/1 model of Huntington's disease.
- Neuregulin-1 receptor tyrosine kinase ErbB4 is upregulated in midbrain dopaminergic neurons in Parkinson disease
- Neuronal Properties, In Vivo Effects, and Pathology of a Huntington's Disease Patient-Derived Induced Pluripotent Stem Cells
- Neuropathology in transplants in Parkinson's disease: Implications for disease pathogenesis and the future of cell therapy.
- 2011
- A deadly spread: cellular mechanisms of α-synuclein transfer.
- Can alpha-synuclein be targeted in novel therapies for Parkinson's disease?
- Caspase signalling controls microglia activation and neurotoxicity.
- Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice.
- Hsa-miR-34b is a Plasma-Stable microRNA that is Elevated in Premanifest Huntington's Disease.
- Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease
- IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.
- Identification of molecules derived from human fibroblast feeder cells that support the proliferation of human embryonic stem cells.
- Journal of Parkinson's Disease Introduction
- Membrane Interaction of α-Synuclein in Different Aggregation States
- Neurogenesis In The R6/2 Mouse Model Of Huntington'S Disease Is Impaired At The Level Of Neurod1
- Reduced neurogenesis in the rat hippocampus following high fructose consumption.
- Signs of Degeneration in 12-22-Year Old Grafts of Mesencephalic Dopamine Neurons in Patients with Parkinson's Disease
- Stage-Specific Modulation of Cortical Neuronal Development by Mmu-miR-134
- Systemic administration of Neuregulin-1ß(1) protects dopaminergic neurons in a mouse model of Parkinson's disease.
- The executioners sing a new song: killer caspases activate microglia
- alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells
- 2010
- A simple method for large-scale generation of dopamine neurons from human embryonic stem cells.
- Are synucleinopathies prion-like disorders?
- Brain injury activates microglia that induce neural stem cell proliferation ex vivo and promote differentiation of neurosphere-derived cells into neurons and oligodendrocytes
- Cell transplantation in Parkinson's disease: problems and perspectives.
- Characterization of Lewy Body Pathology in 12-and 16-Year Old Intrastriatal Mesencephalic Grafts Surviving in a Patient with Parkinson's Disease
- Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease.
- Does A "Prion-Like" Mechanism Contribute to the Spreading of Neuropathology in Parkinson's Disease?
- Foxa2 and Nurr1 Synergistically Yield A9 Nigral Dopamine Neurons Exhibiting Improved Differentiation, Function, and Cell Survival
- GABAergic Differentiation Induced by Mash1 Is Compromised by the bHLH Proteins Neurogenin2, NeuroD1, and NeuroD2.
- Neural grafting in Parkinson's disease Problems and possibilities.
- Neural grafting in Parkinson's disease: problems and possibilities
- Nitric Oxide Stimulates the Proliferation of Neural Stem Cells Bypassing the Epidermal Growth Factor Receptor
- Prion-like transmission of protein aggregates in neurodegenerative diseases.
- 2009
- Absence of striatal newborn neurons with mature phenotype following defined striatal and cortical excitotoxic brain injuries.
- Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment
- Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease.
- BRAIN INJURY ACTIVATES MICROGLIA THAT INDUCE NEURAL STEM CELL PROLIFERATION AND PROMOTE DIFFERENTIATION OF NEUROSPHERE-DERIVED CELLS INTO NEURONS AND TO OLIGODENDROCYTES
- Beyond the brain: widespread pathology in Huntington's disease.
- Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease.
- Involvement of Ngn2, Tbr and NeuroD proteins during postnatal olfactory bulb neurogenesis.
- Lewy body pathology in long-term fetal nigral transplants: is Parkinson's disease transmitted from one neural system to another?
- Mutant huntingtin interacts with {beta}-tubulin and disrupts vesicular transport and insulin secretion.
- Neurogenin2 directs granule neuroblast production and amplification while NeuroD1 specifies neuronal fate during hippocampal neurogenesis.
- Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
- Propagation of host disease to grafted neurons: Accumulating evidence
- 2008
- A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.
- Calpain activation is involved in early caspase-independent neurodegeneration in the hippocampus following status epilepticus
- Critical issues of clinical human embryonic stem cell therapy for brain repair.
- Effects on differentiation of embryonic ventral midbrain progenitors by Lmx1a, MSX1, Ngn2, and Pitx3.
- Emerging restorative treatments for Parkinson's disease.
- From bench to bed: the potential of stem cells for the treatment of Parkinson's disease
- Future Cell- and Gene-Based Therapies for Parkinson's Disease
- Growth factors and feeder cells promote differentiation of human embryonic stem cells into dopaminergic neurons: a novel role for fibroblast growth factor-20.
- Increased metabolism in the R6/2 mouse model of Huntington's disease.
- Increased thirst and drinking in Huntington's disease and the R6/2 mouse
- Islet beta-cell area and hormone expression are unaltered in Huntington's disease.
- Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation.
- Mutant huntingtin can paradoxically protect neurons from death
- Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease.
- Protein-protein interactions in poly-Q disease model
- Research in motion: the enigma of Parkinson's disease pathology spread.
- The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy
- The effect of alpha-synuclein knockdown on MPP plus toxicity in models of human neurons
- Weight loss in Huntington disease increases with higher CAG repeat number
- Weight loss in Huntington's disease is related to the number of CAG repeats
- 2007
- "NeuroStem Chip": a novel highly specialized tool to study neural differentiation pathways in human stem cells.
- Adult neurogenesis in neurodegenerative diseases
- Cocaine- and amphetamine-regulated transcript is increased in Huntington disease.
- Decreased VIP and VPAC(2) receptor expression in the biological clock of the R6/2 Huntington's disease mouse
- Fibroblast growth factor-20 increases the yield of midbrain dopaminergic neurons derived from human embryonic stem cells.
- Large stem cell grafts could lead to erroneous interpretations of behavioral results?
- Loss of SNAP-25 and rabphilin 3a in sensory-motor cortex in Huntington's disease.
- Midbrain expression of Delta-like 1 homologue is regulated by GDNF and is associated with dopaminergic differentiation.
- Reduced expression of PSA-NCAM in the hippocampus and piriform cortex of the R6/1 and R6/2 mouse models of Huntington's disease.
- Restorative cell therapy for Parkinson's disease: A quest for the perfect cell
- Tyrosine hydroxylase expression is unstable in a human immortalized mesencephalic cell line - Studies in vitro and after intracerebral grafting in vivo
- 2006
- Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease.
- Cholinergic neuronal defect without cell loss in Huntington's disease.
- Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
- Enriched Environment Attenuates Cell Genesis in Subventricular Zone After Focal Ischemia in Mice and Decreases Migration of Newborn Cells to the Striatum.
- Failure of transdifferentiation of adult hematopoietic stem cells into neurons.
- High-fat diet impairs hippocampal neurogenesis in male rats.
- Induction of dopaminergic neurons from growth factor expanded neural stem/progenitor cell cultures derived from human first trimester forebrain.
- On the move to stimulate cell plasticity in the substantia nigra in Parkinson's disease.
- Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease
- The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
- Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
- Transplantation in Parkinson's disease: The future looks bright.
- Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: Effect of in vitro differentiation on graft survival and teratoma formation
- Working memory training decreases hippocampal neurogenesis.
- 2005
- Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
- Combining neuroprotective treatment of embryonic nigral donor tissue with mild hypothermia of the graft recipient.
- Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction.
- Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy.
- Increased fiber outgrowth from xeno-transplanted human embryonic dopaminergic neurons with co-implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor.
- Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes.
- Orexin loss in Huntington's disease.
- Platelet-Derived Growth Factor (PDGF-BB) and Brain-Derived Neurotrophic Factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions.
- Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway
- Proteolysis of NR2B by calpain in the hippocampus of epileptic rats.
- Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice.
- Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease.
- Stem cell-based therapy for Parkinson's disease.
- Stromal cell-derived inducing activity does not promote dopaminergic differentiation, but enhances differentiation and proliferation of neural stem cell-derived astrocytes.
- Synaptic dysfunction in Huntington's disease: a new perspective
- The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis.
- The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.
- 2004
- Asialoerythropoetin is not effective in the R6/2 line of Huntington's disease mice
- Harnessing endogenous stem cells to treat neurodegenerative disorders of the basal ganglia.
- No evidence for new dopaminergic neurons in the adult mammalian substantia nigra.
- Stem cell therapy for Parkinson's disease: where do we stand?
- 2003
- Both apoptosis and necrosis occur early after intracerebral grafting of ventral mesencephalic tissue: a role for protease activation.
- Cyclosporin A and Bcl-2 do not inhibit quinolinic acid-induced striatal excitotoxicity in rodents
- Fria radikaler och sjuka proteiner - bovarna bakom Parkinsons sjukdom?Free radicals and ailing proteins - the culprits behind Parkinson’s disease?
- Grafting dopamine neurons in Parkinson's disease: do stem cells have a role in the future?
- Huntington's disease: a synaptopathy?
- Neural transplantation for the treatment of Parkinson's disease
- Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression.
- The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg
- Ultrastructural characterization of dissociated embryonic ventral mesencephalic tissue treated with neuroprotectants.
- 2002
- Characterisation of cell damage and death in embryonic mesencephalic tissue: a study on ultrastructure, vital stains and protease activity.
- Comparison between survival of lazaroid-treated embryonic nigral neurons in cell suspensions, cultures and transplants.
- Dyskinesias following neural transplantation in Parkinson's disease.
- Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line.
- Effects of antioxidant pretreatment on the survival of embryonic dopaminergic neurons in vitro and following grafting in an animal model of Parkinson's disease
- Evidence for Dysfunction of the Nigrostriatal Pathway in the R6/1 Line of Transgenic Huntington's Disease Mice.
- Funding embryonic stem-cell research: will commerce counteract collaboration?
- GDNF treatment in Parkinson's disease: time for controlled clinical trials?
- Huntington's disease: the mystery unfolds?
- Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease.
- Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease.
- Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein.
- Stem cells: hype or hope?
- 2001
- Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice
- Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death
- Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease
- Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration
- Huntingtons sjukdom - ännu ett galet protein?
- Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine
- Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length
- Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene
- The neurobiology of cell transplantation in Parkinson's disease
- 2000
- Additive effects of caspase inhibitor and lazaroid on the survival of transplanted rat and human embryonic dopamine neurons
- Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease
- Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts
- FK506 and cyclosporin A enhance the survival of cultured and grafted rat embryonic dopamine neurons
- Grafting of nigral tissue hibernated with tirilazad mesylate and glial cell line-derived neurotrophic factor
- Improving the survival of grafted dopaminergic neurons: a review over current approaches
- Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease
- 1999
- Caspase inhibition reduces apoptosis and increases survival of nigral transplants
- Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient
- Flunarizine improves the survival of grafted dopaminergic neurons
- Graft survival
- Neuronal death in nigral grafts in the absence of poly (ADP-ribose) polymerase activation
- Patterns of cell death and dopaminergic neuron survival in intrastriatal nigral grafts
- Sequential bilateral transplantation in Parkinson's disease: effects of the second graft
- Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity
- 1997
- 1996
- 1995
- 1994
- 1993
- 1992
- 1987
